Cangene's lead product, WinRho® SDF, is a Rho (D) Immune Globulin (Human) that is licensed for two distinct indications; the prevention of hemolytic disease of the newborn (HDN) and the treatment of immune thrombocytopenic purpura (ITP). WinRho® SDF incorporates a solvent detergent step in its manufacturing process validated to inactivate lipid-enveloped viruses such as Hepatitis B, Hepatitis C, and HIV. WinRho® SDF is nano-filtered using a 35 nm virus filter, which is validated for removing non-lipid-enveloped viruses, such as Hepatitis A and B-19 parvovirus. Click here for information